Dexrazoxane for anthracycline extravasation.
Accidental extravasation of anthracycline-containing anticancer chemotherapy is a feared complication that may lead to progressive tissue damage. The condition may require extensive surgical intervention and often has severe long-term effects. Until a short while ago, there has been no effective treatment against the devastating effect of extravasated anthracycline. However, dexrazoxane has proven highly effective in preventing necrosis in both preclinical and clinical studies and is now approved in Europe (Savene), and has orphan drug status in the USA (Totect) for this indication. Hence, it is the first and only proven effective antidote against anthracycline extravasation injuries.
Langer
Seppo W
SW
Copenhagen University Hospital, Rigshospitalet, Department of Oncology, Section 5073, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. seppo.langer@rh.regionh.dk
D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002614:Chelating Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D011929:Razoxane / Q000627:therapeutic use*; D012871:Skin Diseases / Q000139:chemically induced / Q000188:drug therapy*
D018943:Anthracyclines; D000970:Antineoplastic Agents; D002614:Chelating Agents; D011929:Razoxane